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E-mail address: jfernan1@health.usf.edu (J.W. FernEstrogen depletion following menopause has been correlated with an increased risk of developing
Alzheimer’s disease (AD). We previously explored the beneﬁcial effect of ()-epigallocatechin-3-
gallate (EGCG) on ADmice and found increased non-amyloidogenic processing of amyloid precursor
protein (APP) through the a-secretase a disintegrin and metallopeptidase domain 10 (ADAM10). Our
results in this study suggest that EGCG-mediated enhancement of non-amyloidogenic processing of
APP is mediated by the maturation of ADAM10 via an estrogen receptor-a (ERa)/phosphoinositide
3-kinase/Ak-transforming dependent mechanism, independent of furin-mediated ADAM10 activa-
tion. These data support prior assertions that central selective ER modulation could be a therapeutic
target for AD and support the use of EGCG as a well-tolerated alternative to estrogen therapy in the
prophylaxis and treatment of this disease.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Over the past decade, intense focus has been given to investi-
gating amyloid precursor protein (APP) processing and b-amyloid
(Ab) metabolism as potential therapeutic targets for Alzheimer’s
disease (AD) [1]. More recently, attention has turned toward the
a-secretase/non-amyloidogenic pathway of APP metabolism
[2,3], although its role in AD and potential as a diagnostic marker
have been considered for some time [4–7]. Because of the limited
amount of APP in the cell, it is believed that the amyloidogenic
and non-amyloidogenic pathways compete for substrate in the
process of APP proteolysis [8]. Since a-secretase cleaves withinchemical Societies. Published by E
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andez).the Ab peptide domain, its activation has the added advantage of
precluding neurotoxic Ab peptide formation.
According to prevalence studies, women have a higher risk of
developing AD than men [9,10]. Following menopause, this in-
creased risk of developing AD can be partially attributed to estrogen
depletion [11]. In vitro, 17b-estradiol is associated with accumula-
tion of a soluble fragment of APP resulting fromsoluble amyloid pre-
cursor protein alpha (sAPPa) [12] and reducedAb generation [13]. In
vivo, selective estrogen receptor (ER) modulators reduce Ab accu-
mulation and improve behavioral performance [14,15]. Despite
these promising results, the efﬁcacy of hormone replacement ther-
apy (HRT) in preventing AD in women has remained controversial
[16,17]. While some report that postmenopausal women taking
HRT have both a decreased risk and delayed onset of developing
AD [18], others have found that HRT may result in an increased
dementia risk; either directly or due to an elevation of other risk fac-
tors [10,19]. Given this debate, the fact thatAPPprocessing, ER activ-
ity, and the risk of AD are interrelated is not surprising (reviewed by
Gandy [20]). Because of this, investigators have attempted to ex-
plain the mechanistic underpinnings by which estrogen-mediated
signaling affects Ab accumulation (reviewed by Gandy and Peta-
nceska [21] and Pike et al. [22]).lsevier B.V. All rights reserved.
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the modulation of APP processing. Arguably one of the most prom-
ising green tea compounds being studied is ()-epigallocatechin-
3-gallate (EGCG), which has gained increasing attention due in part
to its reported anti-carcinogenic effects [23,24]. One theory is that
EGCG may act on the ER via its gallate group, thereby mimicking
the 7a-position of 17b-estradiol [25]. Previous reports suggest that
EGCG regulates the production of sAPPa through modulation of
protein tyrosine phosphatases [26,27] and protein kinase C-depen-
dent mechanisms [28,29]. Additionally, EGCG has been shown to
inhibit the activities of pro-inﬂammatory cytokines [30–32] and
a multitude of cellular signaling pathways [31,33,34]; including
those involving the phosphatidylinositol 30-OH kinase (PI3K)/Ak-
transforming (Akt) cascade [35].
We have previously shown that EGCG reduces Ab generation in
N2a cells overexpressing Swedish mutant APP (SweAPP N2a) [36].
In concert with these observations, we found that EGCG promotes
a-site cleavage of APP to enhance formation of a-carboxyl terminal
fragment of APP and sAPPa. These events are associated with ele-
vated a-secretase cleavage activity and enhanced activation of a
disintegrin and metalloprotease domain 10 (ADAM10) [37].
In an effort to further characterize the manner in which stimu-
lation of the non-amyloidogenic/a-secretase pathway leads to
reductions in Ab, our current investigation focuses on mechanisms
by which EGCG alters APP processing. In the present study, we
show that EGCG promotes a-secretase-mediated APP metabolism
through both ERa and furin dependent mechanisms. Speciﬁcally,
EGCG enhanced maturation of ADAM10 via an ERa/PI3K/Akt
dependent mechanism, distinct from EGCG-mediated furin
upregulation.
2. Materials and methods
2.1. Reagents
Green tea-derived EGCG (95% purity by HPLC) was purchased
from Sigma Chemical Co. (St. Louis, Missouri), wortmannin (PI3K
inhibitor) was obtained from Calbiochem (San Diego, CA, USA),
and the highly selective cell permeable PI3K inhibitor, LY294002,
was purchased from Sigma. The selective ERa agonist 1,3,5-tris(4-
hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) was obtained from
Sigma and the selective ERa antagonistmethyl-piperidino-pyrazole
(MPP) and selective ERb antagonist 4-[2-phenyl-5,7-bis(triﬂuoro-
methyl)pyrazolo[1,5-a]pyri midin-3-yl]phenol (PHTPP) were pur-
chased from Tocris Bioscience (Ellisville, MO). The Akt inhibitor
triciribine hydrate (TCN), was obtained from Sigma.
2.2. ELISA
Conditioned media were collected and analyzed at a 1:1 dilu-
tion using the method as previously described [38] and values
were reported as percentage of Ab1x secreted relative to control.
Quantitation of total Ab species was performed according to pub-
lished methods [31]. Brieﬂy, 6E10 (capture antibody) was coated
at 2 lg/ml in PBS into 96-well immunoassay plates overnight at
4 C. The plates were washed with 0.05% Tween-20 in PBS ﬁve
times and blocked with blocking buffer (PBS with 1% BSA, 5% horse
serum) for 2 h at room temperature. Conditioned medium or Ab
standards were added to the plates and incubated overnight at
4 C. Following 3 washes, biotinylated antibody, 4G8 (0.5 lg/ml
in PBS with 1% BSA) was added to the plates and incubated for
2 h at room temperature. After ﬁve washes, streptavidin-horserad-
ish peroxidase (1:200 dilutions in PBS with 1% BSA) was added to
the 96-wells for 30 min at room temperature. Tetramethylbenzi-
dine (TMB) substrate was added to the plates and incubated for
15 min at room temperature. 50 ll of stop solution (2 N N2SO4)was added to each well of the plates. The optical density of each
well was immediately determined by a microplate reader at
450 nm. In addition, Ab140, or Ab142 was separately quantiﬁed
in these samples using the Ab140 Ab142 ELISA kits (IBL-America,
Minneapolis, MN) in accordance with the manufacturer’s instruc-
tions. In all cases, Ab levels were expressed as a percentage of con-
trol (i.e., conditioned medium from untreated SweAPP N2a cells).
2.3. Western blot
Cultured cells were lysed in ice-cold lysis buffer described above,
and an aliquot corresponding to 20–50 lg of total protein was elec-
trophoretically separated using 10% or 12% Tris–glycine gels. Elec-
trophoresed proteins were then transferred to PVDF membranes
(Bio-Rad, Richmond, California), washed in ddH2O, and blocked for
1 h at ambient temperature in Tris-buffered saline (TBS; Bio-Rad)
containing 5% (w/v) non-fat dry milk. After blocking, membranes
were hybridized for 1 h at ambient temperature with various pri-
mary antibodies. Membranes were then washed three times for
5 min each in ddH2O and incubated for 1 h at ambient temperature
with the appropriate HRP-conjugated secondary antibody (1:1000,
Pierce Biotechnology, Inc., Rockford, Illinois). All antibodieswere di-
luted in TBS containing 5% (w/v) of non-fat dry milk. Blots were
developed using the luminol reagent (Pierce Biotechnology). Densi-
tometric analysis was done using the Fluor-S MultiImager™ with
Quantity One™ software (Bio-Rad). For examining sAPPa, condi-
tioned medium was collected following treatment according to a
modiﬁed protocol from Chen and Fernandez [39]. sAPPa was ex-
tracted using 3 K Nanosep centrifugal ﬁlters (Pall Life Sciences,
Ann Arbor, Michigan) and protein concentrate was prepared for
the aforementioned electrophoresis. Antibodies used for western
blot included: ADAM10 antibodies (1:1000; Calbiochem and Chem-
icon), Furin antibody (1:1000; Biomol Intl., Plymouth Meeting, PA),
PC7 antibodies (1:1000; Abcam, Cambridge, MA), phospho-Tyr p85
PI3K binding motif, phospho-Akt (Ser 473), total Akt antibodies
(1:1000, Cell Signaling Technology, Danvers,MA, USA), or actin anti-
body (1:1500; as an internal reference control; Roche).
Densitometric analysis was conducted using the Fluor-S Multi-
Imager with Quantity One software (Bio-Rad) or ImageJ software
(NIH). Images were scanned, protein bands were captured, and a
threshold optical density was obtained that discriminated bands
from background. Densitometric values were reported as area of
positive pixels in reference to an internal control.
2.4. Statistical analysis
All data were normally distributed; therefore, in instances of
single mean comparisons, Levene’s test for equality of variances
followed by t-test for independent samples was used to assess sig-
niﬁcance. In instances of multiple mean comparisons, analysis of
variance (ANOVA) was used, followed by post hoc comparison
using Bonferonni’s method as appropriate. Alpha levels were set
at 0.05 for all analyses. The statistical package for the social sci-
ences release 18 (SPSS Inc., Chicago, Illinois) or StatPlus:mac
(AnalystSoft, Inc., Vancouver, British Columbia, CA) was used for
all data analysis.
3. Results
The presence of estrogen enhances non-amyloidogenic APP a-
secretase cleavage as evidenced by increased sAPPa and decreased
Ab production [40,41]. Thus, the selective actions of estrogen may
represent a therapeutic target for the prevention of toxic Ab spe-
cies and subsequent neurodegeneration. Our prior investigations
suggest a similar mechanismmay be involved in EGCG’s promotion
of sAPPa production [36]. Taken together with studies that
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set out to explore whether EGCG could act fully or partially
through the ER to exert its effect on APP processing.
3.1. Estrogen receptor (ERa) inhibition mitigates EGCG-induced
ADAM10 activation and non-amyloidogenic APP processing in SweAPP
N2a cells
Using similar conditions as in our prior investigations, APP
(Swedish mutant APP 695aa isoform) overexpressing murine neu-
roblastoma N2a cells (SweAPP N2a), known to primarily express
ERa [44], were treated with EGCG at 20 lM [36] in the presence
of various concentrations (0–2.5 lM and 50–200 lM) of highly
selective ERa antagonist MPP [45,46] or highly selective ERb antag-
onist PHTPP, as a structurally related ‘control compound,’ for 12 h
(Fig. 1). Ab140,42 peptides were analyzed in conditioned media
from these cells by ELISA. Consistent with our central hypothesis,
data reveal signiﬁcant increases in Ab140,42 peptide production
by greater than 100% with co-treatment with EGCG and MPP com-
pared to treatment with EGCG alone. No signiﬁcant (P > 0.05)
changes in Ab peptide production were found with control com-
pound and EGCG cotreatment, thereby suggesting that EGCG pro-
motes non-amyloidogenic processing though ERa modulation.
As our prior investigations demonstrated the requirement of
ADAM10 in EGCG promotion of non-amyloidogenic APP metabo-
lism [37], cell lysates from the same SweAPP N2a cells were pre-
pared and subjected to western analysis for ADAM10.
Densitometry ratios of mature (mADAM10) to the proform of
ADAM10 (pro-ADAM10) band densities at various doses of MPP
or control compound treated SweAPP N2a cells show that MPP,
but not control compound, signiﬁcantly inhibits ADAM10 matura-
tion by greater than 70% (Fig. 1). This effect of ERa antagonism cor-
relates with increased production of Ab peptides thereby
indicating downregulation of non-amyloidogenic APP processing.Fig. 1. Estrogen receptor (ERa) inhibition mitigates EGCG-induced ADAM10
activation and non-amyloidogenic APP processing in SweAPP N2a cells. SweAPP
N2a cells (murine neuroblastoma cells overexpressing Swedish mutant 695aa
isoform of APP) were treated with EGCG at 20 lM in the presence of estrogen
inhibitor (MPP, an antagonist at ERa receptor displaying >200-fold selectivity for
ERa over ERb) or a control compound lacking estrogen receptor modulation
properties at various doses as indicated for 12 h. Ab140,42 peptides were analyzed
in conditioned media from these cells by ELISA. Data are represented as Ab140,42
(pg) in total cellular protein (mg) secreted 12 h after co-treatment as indicated
below the ﬁgure. Cell lysates were prepared and subjected to western analysis of
ADAM10 maturation. Densitometric analysis shows the ratio of active mature
(mADAM10) to proform (pro-ADAM10) as indicated below the ﬁgure. One-way
ANOVA followed by post hoc comparison revealed signiﬁcant differences between
MPP doses (**P < 0.005 with n = 3 for each condition), but not control inhibitor
(P > 0.05), for Ab generation and ratio of mADAM10 to pro-ADAM10.Conversely, highly selective ERa agonist, PPT (50–200 lM), was
utilized to compare the effects of ERa activation on downstream
signaling and ADAM10 maturation with the previously observed
effects of EGCG. SweAPP N2a cells were treated for 12 h. Similar
to EGCG, western analysis for ADAM10 revealed enhanced
ADAM10 maturation with PPT although this effect did not reach
statistical signiﬁcance (Supplementary Fig. 1). Interestingly, PPT
and EGCG revealed no additive maturation of ADAM10 possibly
secondary to ERa saturation at trialed doses of these compounds.
Moreover, PPT treatment seemed to attenuate ERa stimulation
by EGCG, perhaps alluding to some form of competition between
the two agonists. (Supplementary Fig. 1). However, taken together
with the MPP results, these results suggest that mechanistically,
EGCG promotion of non-amyloidogenic APP processing mediated
by ADAM10 may require the activity of ERa in these cells.
3.2. EGCG failed to directly promote ADAM10 activation in broken cell
preparations
Having shown that EGCG markedly enhances ADAM10 matura-
tion via ERa-mediated signaling in SweAPP N2a cells, we next set
out to characterize downstream pathway effectors. We hypothe-
sized that EGCG promotion of non-amyloidogenic APP processing
requires structured cellular functions, such as indirect signal trans-
duction cascades or gene regulation, rather than direct activation
of ADAM10 by EGCG. To help rule out the possibility of direct acti-
vation, broken cell preparations from untreated SweAPP N2a cells
were treated with EGCG (10 lM) or PBS (Fig. 2). One hour later,
these cell lysates were subjected to western analysis for ADAM10.
Densitometric analysis indicates that ratios of mADAM10 to pro-
ADAM10 did not vary signiﬁcantly (P > 0.05) suggesting that
ADAM10 activation by EGCG is not mediated through a direct cyto-
solic or molecular interaction with EGCG. These ﬁndings provide
evidence of the requirement for signal transduction pathways
and/or gene regulation in EGCG-mediated ADAM10 activation.
3.3. PI3K/Akt signaling is involved in EGCG-mediated ADAM10
activation and promotion of non-amyloidogenic processing of APP
The involvement of PI3K signaling in the non-genomic activities
of ERs and related downstream signaling events is well known.Fig. 2. EGCG failed to directly promote ADAM10 activation in broken SweAPP N2a
cell preparations. Cell lysates from untreated SweAPP N2a cells and subsequently
treated these lysates with EGCG (10 lM) or PBS. One hour later, these cell lysates
were subjected to western analysis of ADAM10. Densitometric analysis shows the
ratio of mADAM10 to pro-ADAM10 as indicated below the ﬁgure. One-way ANOVA
followed by post hoc comparison revealed no signiﬁcant differences between the
treated conditions (P > 0.05 with n = 4 for each condition) for the ratio of mADAM10
to pro-ADAM10.
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types [35,47]. Gandy and colleagues had previously supported a
role for PI3K activation in promoting sAPPa release from SweAPP
N2a cells [48]. Thus, we next investigated the contribution of
PI3K to EGCG-mediated ADAM10 activation in SweAPP N2a cells.
As shown in Fig. 3, SweAPP N2a cells were treated with EGCG
(20 lM) for 12 h and sAPPa secretion was quantiﬁed by ELISA after
varying treatment concentrations (0–50 lM) of PI3K inhibitor
(wortmannin). Our data show that the PI3K inhibition results in
a dose-dependent decrease in sAPPa release by SweAPP N2a cells
suggesting inhibition of a-secretase activity (Fig. 3A). LDH release
did not vary between control treatment doses of wortmannin (data
not shown). Based on these ﬁndings we hypothesized that PI3K
activation regulates ADAM10 activation in these cells.
In order to test this hypothesis, SweAPP N2a cells were treated
for 12 h with 20 lM EGCG and varying doses of the PI3K inhibitors,
wortmannin (0.2–10 lM) and LY294002 (10–100 lM) [49], lysates
were prepared and subjected to western analysis for ADAM10
(Fig. 3B). Consistent with our sAPPa ELISA ﬁndings, ratios of mA-E
A
B
C
Fig. 3. PI3K/Akt signaling is involved in EGCG-mediated ADAM10 activation and promoti
N2a cells are denoted as a–j and correspond to the following: (a) no treatment, (b)
10 lM + EGCG, (f) WM 400 nM, (g) LY294002 10 lM + EGCG, (h) LY294002 50 lM +
concentration of 20 lM for all conditions unless otherwise indicated. (A) SweAPP N2a cel
treatment concentrations of PI3K inhibitor (WM). (B) pro-ADAM10 and mADAM10 follo
lysates from SweAPP N2a cells by western blot. Densitometry analysis results are repres
interest compared to EGCG control, # represents the protein of interest compared to c
following treatment with various concentrations of EGCG as indicated and analyzed by w
represented as band density ratio of p85 to b-actin (±S.E.M., n = 3, **P < 0.01). (E) Tot
treatment with the PI3K inhibitors and were analyzed in cell lysates from SweAPP N2a c
means ± S.E.M. (n = 3), **P < 0.01 of protein of interest compared to EGCG control, # repDAM10/pro-ADAM10 show a decrease following treatment with
both PI3K inhibitors; suggesting likely involvement of PI3K in
EGCG-mediated ADAM10 activation.
As PI3K has multiple downstream effectors, we next analyzed
phosphorylation of PI3K’s regulatory subunit 85 kD regulatory
subunit of PI3K (p85) in the context of increasing doses of EGCG.
SweAPP N2a cells were treated with varying concentration of EGCG
(0–40 lM) for 4 h, lysed then subjected to western analysis for
PI3K-phospho-p85. Our data indicate a dramatic dose-dependent
increase in phosphorylation at this principle activation site with
EGCG treatments above 5 lM (Fig. 3C and D), altogether suggesting
EGCG promotion of ADAM10 activation and non-amyloidogenic
APP processing involves active PI3K signaling.
To further characterize downstream effectors involved in EGCG-
mediated ADAM10 activation, we examined Akt and phospho-Akt
expression following treatment of SweAPP N2a cells with PI3K
inhibitors (wortmannin and LY294002) in the presence of 20 lM
EGCG after 4 h. Importantly phospho-Akt increased with EGCG
(20 lM) as compared to untreated SweAPP N2a cells, whereasD
on of non-amyloidogenic processing of APP. Various treatment conditions in SweAPP
EGCG, (c) wortmannin (WM) 200 nM + EGCG, (d) WM 400 nM + EGCG, (e) WM
EGCG, (i) LY294002 100 lM + EGCG, (j) LY294002 50 lM. EGCG was used at a
ls were treated with EGCG and sAPPa release was quantitated by ELISA after varying
wing treatment with the PI3K inhibitors, WM and LY294002 were analyzed in cell
ented as band density ratio means ± S.E.M. (n = 3), *P < 0.05, **P < 0.01 of protein of
ontrol without EGCG treatment. (C and D) SweAPP N2a cell lysates were collected
estern analysis for the p85 binding motif of PI3K. Densitometry analysis results are
al Akt and phospho-Akt were assessed as percent of associated control following
ells by western blot. Densitometry analysis results are represented as band density
resents the protein of interest compared to control without EGCG treatment.
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pho-Akt (Fig. 3E). Signiﬁcant group differences were not observed
between total Akt or actin (data not shown). However, in similar
treatment conditions, the Akt inhibitor, TCN, was able to decrease
ADAM10 activation, total and phospho-Akt, but not actin, in the
presence of EGCG (Fig. 4). These data culminate to support the
hypothesis that EGCG may effect ADAM10 activation, and subse-
quent non-amyloidogenic processing of APP, via involvement of
ERa/PI3K/Akt dependent signaling mechanisms.
3.4. EGCG enhances the ADAM10 activating enzyme furin independent
of PI3K activation in SweAPP N2a cells
ADAM10 is known to be regulated by proprotein convertases,
especially PC7 and furin [50]. To determine whether EGCG en-
hances activation of ADAM10 through the upstream regulation of
proprotein convertases, SweAPP N2a cells were treated with vary-
ing concentrations of EGCG (0–40 lM) for 4 h, lysed and subjected
to western analysis for furin or PC7. Results indicated that expres-
sion of furin but not PC7 isoforms were increased nearly 4–5-fold
compared with controls (Fig. 5A–D).Fig. 4. Akt inhibition by triciribine hydrate (TCN) reduces ADAM10 activation, total Akt,
SweAPP N2a cells are denoted as (a–f) and correspond to the following: (a) no treatm
50 lM + EGCG. EGCG was used at a concentration of 20 lM for all conditions unless othe
Akt inhibitor (TCN) in the presence and absence of EGCG. Cell lysates were prepared a
(Ser473), and b-actin (internal control). (B) Densitometric analysis shows the ratio of ac
One-way ANOVA revealed signiﬁcant differences between TCN treated and control cells
presence of EGCG. # represents the protein of interest compared to control without EG
phospho-Akt (Ser473) and represented as percent of associated control (SweAPP N2a ± EG
of interest compared to EGCG control, # represents the protein of interest compared to c
were present at concentrations of 5 and 10 lM for total Akt in the presence of EGCG o
presence and absence of EGCG.Regulation of furin is complex and appears to involve both
adaptor proteins and autoactivation depending on the environ-
ment of its cellular compartment [51], however, given our ﬁndings
of PI3K/Akt involvement in EGCG promotion of ADAM10 activation
via ERa, we explored the ability of varying doses of PI3K inhibitor
to affect EGCG-mediated furin upregulation. SweAPP N2a cells
were treated with EGCG (20 lM) in the presence of PI3K inhibitor
(wortmannin; 0–50 lM) for 4 h, lysates were prepared and ana-
lyzed by western blot (Fig. 5E and F). Interestingly, PI3K inhibition
failed to inhibit EGCG-associated furin activation; implicating a
divergent, non-PI3K-mediated pathway for EGCG-induced furin
activation.
To investigate whether EGCG-mediated furin upregulation
could result from non-PI3K dependent activities of ERa, SweAPP
N2a cells were treated for overnight in the presence of EGCG
(20 lM) and either ERa antagonist (MPP) or agonist (PPT) (Sup-
plementary Fig. 1). Results showed no signiﬁcant changes in
furin protein levels between EGCG and either MPP or PPT there-
by altogether implicating an alternative ERa- and PI3K-indepen-
dent mechanism associated with EGCG-induced furin
upregulation.and phosphorylated Akt, in the presence of EGCG. Various treatment conditions in
ent, (b) EGCG, (c) TCN 5 lM, (d) TCN 1 lM + EGCG, (e) TCN 5 lM + EGCG, (f) TCN
rwise indicated. (A) SweAPP N2a cells were treated with varying concentrations of
nd subjected to western analysis of ADAM10 maturation, total Akt, phospho-Akt
tive mature (mADAM10) to proform (pro-ADAM10) as indicated below the ﬁgure.
at concentrations of 5 and 10 lM (**P < 0.01 with n = 3 for each condition) in the
CG treatment. (C and D) Densitometric analysis was performed on total Akt and
CG) following treatment with TCN ± S.E.M. (n = 3), *P < 0.05 and **P < 0.01 of protein
ontrol without EGCG treatment. Signiﬁcant differences between treated and control
nly, while phospo-Akt was signiﬁcantly reduced for all TCN concentrations in the
AC
E
F
B
D
Fig. 5. EGCG enhances ADAM10 activating enzyme furin independent of PI3K activation in SweAPP N2a cells. (A and B) Expression of furin and PC7 was analyzed in lysates
from SweAPP N2a cells treated with EGCG at concentrations indicated for 4 h by western blot. (C and D) Densitometric analysis reveals the band density ratio of furin or PC7
isoforms to b-actin (internal reference control). One-way ANOVA followed by post hoc comparison revealed signiﬁcant differences (P < 0.01, n = 3, data presented as ±S.E.M.)
when comparing each concentration of EGCG and respective furin to actin ratio either to control (PBS) or vs. other EGCG dose. Interestingly EGCG treatments did not
signiﬁcantly affect PC7 isoforms expression (B and D). (E) Expression of furin was analyzed in lysates from SweAPP N2a cells treated with EGCG (20 lM) in the presence of
PI3K inhibitor (wortmannin) at concentrations indicated for 4 h by western blot. (F) Densitometric analysis reveals the band density ratio of furin to b-actin (internal
reference control). One-way ANOVA followed by post hoc comparison revealed no signiﬁcant differences (n = 3, data presented as ±SEM) when comparing each concentration
of PI3K inhibitor and respective furin to b-actin ratio.
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Therapeutic modalities that oppose cleavage of APP into Ab
peptides and attenuate resultant cerebral amyloidosis have be-
come a primary focus in the last decade. The main targets have
been b- and c-secretases, the two proteases that cleave APP at
the N- and C-terminus of the Ab peptide and are thus directly
responsible for Ab peptide generation. Although mechanistically
promising, early clinical studies aimed at treating amyloid-associ-
ated neurodegenerative disease by modulating these proteases
have been disappointing, likely because adequate doses for treat-
ment are limited by clinical toxicity [52]. A different strategy,
namely the activation of a-secretase, has only recently begun to
be evaluated for its therapeutic potential despite the fact that it
cleaves within the Ab peptide domain and thus precludes Ab pep-
tide generation [2–4,7].
Although estrogen replacement therapy remains controversial
due largely to adverse effects reported in clinical studies looking
at its use in postmenopausal women, the development of selective
estrogen modulators for AD continues to be pursued vigorously
[14,22]. EGCG, a known modulator of APP processing with function
at the ER, is believed to be responsible for the health beneﬁts asso-
ciated with the consumption of green tea, and has been shown by
pharmacokinetic and safety studies to be generally well tolerated
[53]. Our laboratory has previously shown that EGCG can increase
non-amyloidogenic processing of APP through promotion of the a-
secretase ADAM10, which consequently reduced Ab deposition andimproved cognition in AD mice [36,37]. In the present study, we
further characterize the mechanisms responsible for EGCG’s stim-
ulation of ADAM10 in SweAPP N2a cells by elucidating the involve-
ment of key effectors including ERa, PI3K and Akt (Figs. 1–5). In
addition, we corroborate a role for furin in ADAM10 activation
and present evidence suggesting that EGCG upregulates furin by
mechanisms independent from the ERa/PI3K/ADAM10 pathway
proposed here (Fig. 5 and Supplementary Fig. 1).
As suggested by our prior studies, SweAPP N2a cells treated
with EGCG displayed a dramatic increase in the mature active form
of ADAM10, associated with enhanced metabolites indicative of
non-amyloidogenic APP processing (Fig. 1). When these cells were
treated concurrently with the selective ERa antagonist MPP and
EGCG, dose-dependent reductions in ADAM10 maturation were
observed. The ERa agonist PPT appeared to increase ADAM10 mat-
uration alone, but also possibly compete for ER binding in the pres-
ence of EGCG; results which further support the involvement of
ERa in EGCG’s promotion of non-amyloidogenic processing of
APP (Fig. 1 and Supplementary Fig. 1). As suggested by other
groups, this effect may represent direct activation of membrane
associated ERs [42]. Consistent with our and others’ ﬁndings impli-
cating regulated signal transduction mechanisms mediating
EGCG’s non-amyloidogenic properties, EGCG failed to show a sig-
niﬁcant ability to enhance activation of ADAM10 in broken cell
preparations (Fig. 2).
Our ﬁnding that EGCG may act through the ER is consistent
with previous oncologic ﬁndings in which EGCG was capable of
Fig. 6. Working model of effects of EGCG on APP processing. In this model, EGCG activates membrane associated estrogen receptors in a ligand dependent, non-genomic,
manner setting in motion receptor tyrosine phosphorylation of the p85 regulatory subunit of PI3K. Subsequently PIP2 is converted to PIP3, which, in turn, activates Akt to
negatively regulate GSK3 and numerous other downstream effectors required for cellular growth and survival. In our model, Akt may also act directly on APP by
phosphorylating C-terminal tyrosine sites or indirectly through the adaptor protein Shc to effect APP phosphorylation [74]. Substrate modiﬁcations such as phosphorylation
and/or association with adaptor proteins may enhance the binding capacity and substrate-mediated activation of ADAM10 directly [71] or indirectly through autoactivation
[51] and enhanced expression of furin, also observed after EGCG treatment.
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gether, these data suggest a mechanistic clue as to why gender dif-
ferences and estrogen depletion have been described in AD and
other APP related disorders [56–59]; including multiple studies
which support an association between certain polymorphisms of
the ESR1 gene and the risk of developing AD [60–63].
Although several signal transduction pathways have been
implicated in ER and EGCG-mediated pathways, we decided to fo-
cus on the PI3K second messenger system as this system canoni-
cally involves modulation of GSK-3; a molecule considered to
play a key role in AD via the regulation of presenilins and tau
[64–66], and ERa has been shown to interact with PI3K/Akt/
GSK3 signaling in neuronal cells [44]. However, controversy exists
over whether ER-mediated neuroprotection is dependent on PI3K/
Akt activation, but not MAPK/ERK signaling [67,68] or whether the
coordinated activity of Akt and ERK is responsible for signaling via
the ER [69,70]. Whereas the involvement of PI3K signaling subse-
quent to activation of ERs is well known, comparatively fewer
studies have shown EGCG’s capacity to activate PI3K in various cell
type [35,47]. We ﬁnd here that SweAPP N2a cells treated with the
PI3K inhibitors and EGCG display lower concentrations of sAPPa in
media, less activated ADAM10, and less phospho-Akt. Accordingly,
PI3K-phospho-p85 was upregulated after EGCG treatment
(Fig. 3D); implicating involvement of PI3K in EGCG-mediated
ADAM10 activation. Despite these ﬁndings, involvement of ERa/
MAPK/ERK signaling in EGCG-mediated ADAM10 activation cannot
be ruled out.
ADAM10 is known to be regulated by proprotein convertases,
especially PC7 and furin [50]. Subsequent experiments aimed at
determining whether the EGCG-mediated ERa-PI3K/Akt/ADAM10
pathway involved PC7 or furin upregulation yielded surprising re-
sults. As seen in Fig. 5, EGCG enhanced ADAM10 activation was
associated with dramatic elevations in furin protein, however thisfurin upregulation was neither affected by PI3K inhibition nor al-
tered by ERamodulation (Supplementary Fig. 1). Collectively it ap-
pears that EGCG enhances ADAM10 activation in both a furin-
independent manner via the ERa/PI3K pathway and in a divergent
furin dependent manner. Furthermore, PI3K-independent, ERa/
MAPK/ERK signaling could also be responsible for furin upregula-
tion in the context of ECGC treatment in these cells. Taken with
other reports, this suggests that tight cellular control of this a-
secretase is maintained by multiple independently regulated
mechanisms, and speaks to the importance of ADAM10’s role in
cellular function [71,72] (reviewed by Thomas [73]).
In summary, a possible model for activation of ADAM10 by
EGCG in SweAPP N2a cells is represented in Fig. 6 (see ﬁgure leg-
end for details). Altogether the events depicted, individually or
synergistically, lead to enhanced ADAM10 maturation and promo-
tion of non-amyloidogenic processing of APP following EGCG
treatment.
Our ﬁndings support a role for therapeutic selective ERamodu-
lation in the attenuation or prevention of toxic oligomeric Ab spe-
cies formation in AD and related disorders. In addition, our data
provide a basic mechanistic rationale for previous clinical ﬁndings
revealing an increased risk of AD in the context of age-dependent
estrogen depletion in women. Further exploration of EGCG’s effects
on estrogen modulation, activation of ADAM10, and promotion of
non-amyloidogenic APP processing is warranted to support the
use of this compound as a safe alternative to estrogen replacement
therapy in the prevention and treatment of AD.
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